Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer-Reference-Cited by-同舟云学术

Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer

Published:2013-10-01 Issue:23 Volume:119 Page:4145-4153
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ma Brigette B. Y.¹,Chan Stephen L.¹,Ho Wing M.¹,Lau Wilson¹,Mo Frankie¹,Hui Edwin P.¹,Chan Charles¹,Poon Annette¹,Dattatray Rasalkar D.²,Wong S. C. Cesar³,To Ka F.⁴,King Ann D.²,Ahuja Anil²,Chan Anthony T. C.¹

Affiliation:

1. Department of Clinical Oncology, Sir Y.K. Pao Centre for Cancer, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences; Chinese University of Hong Kong; Hong Kong SAR China

2. Department of Imaging and Interventional Radiology; Prince of Wales Hospital; Hong Kong SAR China

3. Department of Health Technology and Informatics; the Hong Kong Polytechnic University; Hong Kong SAR China

4. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital; Chinese University of Hong Kong; Hong Kong SAR China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28327/fullpdf

Reference36 articles.

1. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial;Tournigand;J Clin Oncol.,2012

2. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer;Weickhardt;J Clin Oncol.,2012

3. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models;Ouchi;Cancer Chemother Pharmacol.,2006

4. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839);Azzariti;Biochem Pharmacol.,2004

5. Characterization of sequence-dependent synergy between ZD1839 (“Iressa”) and oxaliplatin;Xu;Biochem Pharmacol.,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the role of wound‐healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications;International Wound Journal;2024-03

2. Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer;Scientific Reports;2020-10-06

3. EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency;Clinical Chemistry and Laboratory Medicine (CCLM);2019-07-16

4. A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer;Anticancer Research;2018-12-27

5. Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway;Molecular Carcinogenesis;2018-10-05